跳至主要内容
临床试验/NCT05315817
NCT05315817终止不适用

Safety and Performance Evaluation of multiPlus Dialysate During CRRT

Fresenius Medical Care Deutschland GmbH1 个研究点 分布在 1 个国家目标入组 1 人开始时间: 2022年5月31日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
终止
入组人数
1
试验地点
1
主要终点
Serum creatinine removal

研究概览

简要总结

Assessment of the performance of multiPlus dialysate based on the serum creatinine removal 6 hours (360 min) after start of continuous veno-venous haemodialysis/ haemodiafiltration [CVVHD(F)].

multiPlus is a phosphate-containing dialysis solution for the use in continuous renal replacement therapy (CRRT) during acute kidney injury (AKI).

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Signed and dated informed consent form by investigator and by
  • •a) the study patient: if patient is able to consent
  • •b) the legal representative: if patient is unable to consent:
  • •c) an independent consultant: in case of emergency
  • •if c) either legal representative or study patient, whichever can be done sooner, should be informed by the investigator as soon as possible. If the informed consent has been obtained by the legal representative (b or emergency scenario) informed consent to continue the participation in the clinical investigation shall be obtained from the subject as soon as he or she is capable of giving informed consent (According to the MDR - Article 68 - Clinical investigations in emergency situations)
  • •Minimum age of 18 years
  • •Ability to understand the nature and requirements of the study (if patient is conscious)
  • •Study specific:
  • •Body weight greater than 40 kg
  • •Acute Kidney Injury (AKI) with clinical indication for CVVHD/CVVHDF
  • •Vascular access allowing blood flow of min 50mL/min
  • •Estimated life expectancy greater than 3 days

排除标准

  • •Any conditions which could interfere with the patient's ability to comply with the study
  • •In case of female patients: pregnancy (negative pregnancy test for women below 55 years) or lactation period
  • •Participation in an interventional clinical study during the preceding 30 days
  • •Previous participation in the same study
  • •SARS-CoV 2 positive
  • •Study specific
  • •Hyperphosphataemia (>4.5 mg/dL)
  • •Hypersensitivity to heparin or known history of heparin induced thrombocytopenia (HIT Type II)
  • •Uncontrolled bleeding and coagulation disorders
  • •Decision to limit therapeutic interventions
  • •Advanced malignancy (not including myeloma)
  • •Dementia (if definitely not an acute confusional state from uraemia or other acute illness)
  • •Advanced cirrhosis with encephalopathy in the absence of possible liver transplantation

研究组 & 干预措施

multiPlus dialysate

Experimental

Treatment of acute kidney injury patients either with continuous veno-venous haemodialysis (CVVHD) or continuous veno-venous haemodiafiltration (CVVHDF) using the multiPlus dialysate.

干预措施: multiPlus dialysate (Device)

结局指标

主要结局

Serum creatinine removal

时间窗: 360 min after start

The primary variable of this clinical investigation is serum creatinine removal (arterial pre-filter sample taking) assessed 6 hours (360 min) after start of CVVHD(F).

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验